Healthcare Providers

Your patients look to you to guide them through their patient journey. CELLSEARCH® can provide you with a detailed map of the road ahead.

The CELLSEARCH® enrichment and enumeration test is a valuable tool for use in patient management that provides a standardized assessment of circulating tumor cell (CTC) counts that help to inform clinical decisions—all with a simple blood draw.

The lab-developed tests are only available in the US and are performed in our lab in Huntingdon Valley, PA, which is CLIA certified and ISO 15189-accredited for CELLSEARCH® CTC testing. With over 15 years of clinical lab experience and 20+ successful regulatory audits, our lab team has the experience and knowledge to provide you with critical clinical data you can trust.

Test Menu
  • CMMC enumeration
  • CTC enumeration
  • HER2 biomarker with enumeration
  • PD-L1 biomarker with enumeration

Benefits of liquid biopsy

  • Identify biomarkers for rare cells leveraging the Gold Standard CELLSEARCH® platform
  • Non-invasive tool with high specificity and sensitivity
  • Easily accessible and highly standardized
  • Fast and reliable results

Our proprietary tubes allow sample collection from anywhere around the United States

  • CellSave Preservative Tubes provide sample stability for up to 96 hours, while the CellRescue™ Preservative Tubes provide sample stability for up to 120 hours. Both tubes allow storage at room temperature

The performance, characteristics, safety, and effectiveness of the PD-L1 Biomarker with Enumeration, CMMC Enumeration, HER2 Biomarker with Enumeration, and CMC Biomarker with Enumeration lab-developed tests have not been cleared or approved by the FDA.

The CELLSEARCH® Circulating Tumor Cell (CTC) test is FDA-cleared for detecting CTCs in cancer patients with metastatic breast, prostate*, or colorectal cancer.

*Metastatic prostate cancer patients were defined as having two consecutive increases in the serum marker prostate-specific antigen above a reference level, despite standard hormonal management. These patients are commonly described as having androgen-independent, hormone-resistant, or castration-resistant prostate cancer.